Peer-influenced content. Sources you trust. No registration required. This is HCN.
GoodRx Health
Early detection remains paramount – 90% of early-stage colon cancer patients survive at least 5 years after diagnosis, emphasizing the critical importance of timely screening.
Family Medicine/General Practice October 29th 2024
Medical Professionals Reference (MPR)
In the BLUE-C trial, Cologuard Plus demonstrated a 93.9% sensitivity for colorectal cancer detection, significantly outperforming the 67.3% sensitivity of FIT.
Family Medicine/General Practice October 16th 2024
MDLinx
Medical errors are now recognized as the third leading cause of death in the US, emphasizing the urgent need for improved safety measures in healthcare settings.
Anesthesiology September 10th 2024
The New England Journal of Medicine
In a phase 2 study of patients with locally advanced mismatch repair–deficient colon cancer, treatment with neoadjuvant nivolumab plus ipilimumab resulted in a 98% pathological response rate and a 68% pathological complete response rate, with no recurrence of disease observed over a median follow-up of 26 months.
Oncology, Medical June 10th 2024
Epoch Health
Recent findings suggest extending follow-up colonoscopy intervals to 15 years for patients without a family history of colorectal cancer and with initial negative results. This could reduce unnecessary procedures without significantly increasing cancer risk.
Gastroenterology June 4th 2024
Cleveland Clinic Journal of Medicine
Microscopic colitis, often masked in routine diagnostic evaluations, necessitates a histological approach for accurate diagnosis. The disease’s association with specific medications underscores the need for careful patient medication reviews.
Gastroenterology April 15th 2024